View of Therapeutic monoclonal antibodies: scFv patents as a marker of a new class of potential biopharmaceuticals

Return to Issue Details Therapeutic monoclonal antibodies: scFv patents as a marker of a new class of potential biopharmaceuticals Download Download PDF